MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leppik, R. A.
Right arrow Articles by Paquet, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leppik, R. A.
Right arrow Articles by Paquet, J. L.

Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor

RA Leppik, RC Miller, M Eck and JL Paquet

Marion Merrell Dow Research Institute, Strasbourg, France.

The purpose of this study was to explore the role of acidic amino acids in the allosteric behavior of gallamine at the m2 receptor. This was achieved by first mutating the acidic residues to neutral residues by site-directed mutagenesis. Both the parent and mutated receptors were expressed in mouse fibroblast A9L cells and characterized pharmacologically. The two main methods used were (i) Schild analysis of equilibrium binding data and (ii) study of the effect of gallamine on the dissociation kinetics of N-methylscopolamine. The Schild analysis gave an estimate of the affinity of gallamine for the allosteric site (KdA) and also a measure of the level of cooperativity (alpha) between the allosteric and primary binding sites. For the receptors studied, a good agreement was found between the alpha KdA values calculated from the Schild analysis and the IC50 values for the effect of gallamine on the N-methylscopolamine off-rate. One mutated receptor, in which the acidic EDGE (Glu-Asp-Gly-Glu) sequence of the putative third outer domain was changed to the neutral LAGQ (Leu-Ala- Gly-Gin) sequence, displayed an 8-fold reduction in affinity for gallamine at the allosteric site, in comparison with the parent receptor. The level of cooperatively between the allosteric and primary binding sites in this mutant was 46% of that of the parent receptor. A second mutated receptor, in which Asp-97 (near the top of putative transmembrane domain 3) was changed to asparagine, was found to have a level of cooperativity between sites 58% of that of the parent but was found not to be affected with respect to the affinity of gallamine for the allosteric site. When all of the acidic groups on the outer side were changed to neutral residues, there was still only an 8.6-fold reduction in gallamine affinity for the allosteric site, but the level of cooperativity was reduced to 19% of that found in the parent receptor. The results suggest that the allosteric site for gallamine binding in the m2 receptor residues at or near the putative third outer domain and that both the EDGE motif and Asp-97 play an essential role in the interaction between the two sites. However, none of the acidic amino acids mutated were found to be critical for binding at the allosteric site.

Volume 45, Issue 5, pp. 983-990, 05/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
F. J. Ehlert and M. T. Griffin
Two-State Models and the Analysis of the Allosteric Effect of Gallamine at the M2 Muscarinic Receptor
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 1039 - 1060.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Jager, C. Schmalenbach, S. Prilla, J. Schrobang, A. Kebig, M. Sennwitz, E. Heller, C. Trankle, U. Holzgrabe, H.-D. Holtje, et al.
Allosteric Small Molecules Unveil a Role of an Extracellular E2/Transmembrane Helix 7 Junction for G Protein-coupled Receptor Activation
J. Biol. Chem., November 30, 2007; 282(48): 34968 - 34976.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
V. A. Avlani, K. J. Gregory, C. J. Morton, M. W. Parker, P. M. Sexton, and A. Christopoulos
Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands
J. Biol. Chem., August 31, 2007; 282(35): 25677 - 25686.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. Steinfeld, M. Mammen, J. A. M. Smith, R. D. Wilson, and J. R. Jasper
A Novel Multivalent Ligand That Bridges the Allosteric and Orthosteric Binding Sites of the M2 Muscarinic Receptor
Mol. Pharmacol., August 1, 2007; 72(2): 291 - 302.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. T. May, V. A. Avlani, C. J. Langmead, H. J. Herdon, M. D. Wood, P. M. Sexton, and A. Christopoulos
Structure-Function Studies of Allosteric Agonism at M2 Muscarinic Acetylcholine Receptors
Mol. Pharmacol., August 1, 2007; 72(2): 463 - 476.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-P. Huang and J. Ellis
Mutational Disruption of a Conserved Disulfide Bond in Muscarinic Acetylcholine Receptors Attenuates Positive Homotropic Cooperativity between Multiple Allosteric Sites and Has Subtype-Dependent Effects on the Affinities of Muscarinic Allosteric Ligands
Mol. Pharmacol., March 1, 2007; 71(3): 759 - 768.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. A. Lanzafame, P. M. Sexton, and A. Christopoulos
Interaction Studies of Multiple Binding Sites on M4 Muscarinic Acetylcholine Receptors
Mol. Pharmacol., August 1, 2006; 70(2): 736 - 746.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Fruchart-Gaillard, G. Mourier, C. Marquer, A. Menez, and D. Servent
Identification of Various Allosteric Interaction Sites on M1 Muscarinic Receptor Using 125I-Met35-Oxidized Muscarinic Toxin 7
Mol. Pharmacol., May 1, 2006; 69(5): 1641 - 1651.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-P. Huang, S. Prilla, K. Mohr, and J. Ellis
Critical Amino Acid Residues of the Common Allosteric Site on the M2 Muscarinic Acetylcholine Receptor: More Similarities than Differences between the Structurally Divergent Agents Gallamine and Bis(ammonio)alkane-Type Hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide
Mol. Pharmacol., September 1, 2005; 68(3): 769 - 778.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
J.-C. Peter, J. Tugler, P. Eftekhari, D. Maurice, J. Hoebeke, and J.-C. Roegel
Effects on heart rate of an anti-M2 acetylcholine receptor immune response in mice
FASEB J, June 1, 2005; 19(8): 943 - 949.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Jakubik, A. Krejci, and V. Dolezal
Asparagine, Valine, and Threonine in the Third Extracellular Loop of Muscarinic Receptor Have Essential Roles in the Positive Cooperativity of Strychnine-Like Allosteric Modulators
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 688 - 696.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. Lanzafame and A. Christopoulos
Investigation of the Interaction of a Putative Allosteric Modulator, N-(2,3-Diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) Methanamine Hydrobromide (SCH-202676), with M1 Muscarinic Acetylcholine Receptors
J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 830 - 837.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
U. Voigtlander, K. Johren, M. Mohr, A. Raasch, C. Trankle, S. Buller, J. Ellis, H.-D. Holtje, and K. Mohr
Allosteric Site on Muscarinic Acetylcholine Receptors: Identification of Two Amino Acids in the Muscarinic M2 Receptor That Account Entirely for the M2/M5 Subtype Selectivities of Some Structurally Diverse Allosteric Ligands in N-Methylscopolamine-Occupied Receptors
Mol. Pharmacol., July 1, 2003; 64(1): 21 - 31.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Trankle, O. Weyand, U. Voigtlander, A. Mynett, S. Lazareno, N. J. M. Birdsall, and K. Mohr
Interactions of Orthosteric and Allosteric Ligands with [3H]Dimethyl-W84 at the Common Allosteric Site of Muscarinic M2 Receptors
Mol. Pharmacol., July 1, 2003; 64(1): 180 - 190.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z.-G. Gao, S.-K. Kim, A. S. Gross, A. Chen, J. B. Blaustein, and K. A. Jacobson
Identification of Essential Residues Involved in the Allosteric Modulation of the Human A3 Adenosine Receptor
Mol. Pharmacol., May 1, 2003; 63(5): 1021 - 1031.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Swaminath, T. W. Lee, and B. Kobilka
Identification of an Allosteric Binding Site for Zn2+ on the beta 2 Adrenergic Receptor
J. Biol. Chem., January 3, 2003; 278(1): 352 - 356.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Buller, D. P. Zlotos, K. Mohr, and J. Ellis
Allosteric Site on Muscarinic Acetylcholine Receptors: A Single Amino Acid in Transmembrane Region 7 Is Critical to the Subtype Selectivities of Caracurine V Derivatives and Alkane-Bisammonium Ligands
Mol. Pharmacol., January 1, 2002; 61(1): 160 - 168.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Krejci and S. Tucek
Changes of Cooperativity between N-Methylscopolamine and Allosteric Modulators Alcuronium and Gallamine Induced by Mutations of External Loops of Muscarinic M3 Receptors
Mol. Pharmacol., October 1, 2001; 60(4): 761 - 767.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Ellis and M. Seidenberg
Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors
Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
R. A. Leppik, A. Mynett, S. Lazareno, and N. J. M. Birdsall
Allosteric Interactions between the Antagonist Prazosin and Amiloride Analogs at the Human alpha 1A-Adrenergic Receptor
Mol. Pharmacol., March 1, 2000; 57(3): 436 - 445.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
A. L. Gnagey, M. Seidenberg, and J. Ellis
Site-Directed Mutagenesis Reveals Two Epitopes Involved in the Subtype Selectivity of the Allosteric Interactions of Gallamine at Muscarinic Acetylcholine Receptors
Mol. Pharmacol., December 1, 1999; 56(6): 1245 - 1253.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Jakubik and J. Wess
Use of a Sandwich Enzyme-linked Immunosorbent Assay Strategy to Study Mechanisms of G Protein-coupled Receptor Assembly
J. Biol. Chem., January 15, 1999; 274(3): 1349 - 1358.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
M. P. Caulfield and N. J. M. Birdsall
International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors
Pharmacol. Rev., June 1, 1998; 50(2): 279 - 290.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. A. Leppik, S. Lazareno, A. Mynett, and N. J. M. Birdsall
Characterization of the Allosteric Interactions between Antagonists and Amiloride Analogues at the Human alpha 2A-Adrenergic Receptor
Mol. Pharmacol., May 1, 1998; 53(5): 916 - 925.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. E. Porter, S. E. Edelmann, D. J. Waugh, M. T. Piascik, and D. M. Perez
The Agonism and Synergistic Potentiation of Weak Partial Agonists by Triethylamine in alpha 1-Adrenergic Receptor Activation: Evidence for a Salt Bridge as the Initiating Process
Mol. Pharmacol., April 1, 1998; 53(4): 766 - 771.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
C. Tränkle, I. Andresen, G. Lambrecht, and K. Mohr
M2 Receptor Binding of the Selective Antagonist AF-DX 384: Possible Involvement of the Common Allosteric Site
Mol. Pharmacol., February 1, 1998; 53(2): 304 - 312.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics